Clinical trials: Early-Stage Breast Cancer
Breast Cancer, Radiation Toxicity
Modulated Accelerated RAdiotherapy in Early Breast Cancer
This trial was a retrospective study on postoperative accelerated hypofractionated IMRT (MARA-1) in patients with early stage breast carcinoma, to compare late toxicity after this treatment and standard fractionated RT delivered…
- Trial name
- NCT03461224
- Testing
- accelerated hypofractionated RT, conventional fractionated RT
- Volunteers
- 447 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Neoplasms, Breast Cancer
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early…
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma
- Trial name
- I-SPY (NCT01042379)
- Testing
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin
- Where
- 42 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Breast Cancer, Ovarian Cancer
Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer
A phase I trial to determine the recommended phase two dose of the combination of carboplatin and olaparib.
- Conditions
- Breast Cancer, Ovarian Cancer, Advanced Cancer
- Trial name
- REVIVAL (NCT02418624)
- Testing
- carboplatin, olaparib
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Evaluation of the Effect of Regular Physical Exercise in Breast Cancer.
This study, titled "Evaluation of the effect of regular physical exercise in women with breast cancer on adjuvant hormone therapy," is a research project designed to see how guided exercise can help women recovering from breast…
- Trial name
- NCT07893327
- Testing
- Supervised exercise program
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer
Randomized trial that compares a personalized digitally-enabled pathway delivered by a mobile application in addition to standard of care vs.
- Trial name
- HOPE (NCT06781996)
- Testing
- multimodal Resilience© digital companion, Standard supportive care
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Breast Neoplasm
Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical Outcome
Breast cancer is the most common cancer among women in Norway. In 2016, 3402 new cases were diagnosed (3371 in women). Breast cancer is still the second most common cause of death from cancer among women with 585 breast cancer…
- Trial name
- NCT03761420
- Where
- Norway
- Volunteers
- 1,411 people
- Sponsor
- St. Olavs Hospital
Breast Cancer, HR Positive, HER2 Positive Breast Cancer
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
This is a single-arm, prospective, multicenter, phase II clinical study evaluating the efficacy and safety of a chemotherapy-free neoadjuvant regimen in patients with HR-positive/HER2-positive (HR+/HER2+) early or locally…
- Trial name
- NCT07795424
- Testing
- Culmerciclib, Letrozole, Trastuzumab (TQB211)
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shengjing Hospital
Breast Cancer
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer
RATIONALE: Diagnostic procedures, such as PET scans, may help in learning how well hormone therapy and trastuzumab work to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- NCT00362973
- Testing
- laboratory biomarker analysis, needle biopsy, positron emission tomography
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of Washington
Breast Cancer With Low to Intermediate HER2 Expression
Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women…
- Trial name
- POCEB (NCT07630402)
- Testing
- Echocardiogram
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
ctDNA Monitoring, Breast Cancer
Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer
The goal of this clinical study is to determine whether monitoring ctDNA and treating patients who become ctDNA-positive with abemaciclib can help prevent the recurrence of hormone receptor-positive, HER2-negative breast cancer…
- Trial name
- ARCHE (NCT07292207)
- Testing
- Abemaciclib 150 MG Oral Tablet
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Nagoya City University
Breast Cancer
Efficacy of Capecitabine With Adjuvant Radiotherapy in Treatment of Early Stages Breast Cancer (Retrospective Study).
1- Determine the efficacy and safety of concurrent capecitabine and external beam irradiation in patients with early stages breast cancer.
- Trial name
- NCT04815616
- Testing
- Radiotherapy
- Volunteers
- 47 people
- Sponsor
- Assiut University
HER2 + Breast Cancer
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.
- Trial name
- NCT07294534
- Testing
- HLX87+HX22, HLX87 + Pertuzumab, TCbHP
- Volunteers
- 817 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Breast Cancer
DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.
- Trial name
- NCT02838225
- Testing
- Docetaxel, Doxorubicin, Docetaxel, Doxorubicin, Cyclophosphamide
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
This is a prospective, open-label, randomized phase III study assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer.
- Trial name
- NCT00130533
- Testing
- Capecitabine
- Where
- 48 sites in Spain
- Volunteers
- 876 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.
To determine the effects of endurance exercise training on cardiopulmonary fitness in breast cancer patients undergoing neoadjuvant chemotherapy.
- Trial name
- NCT00405678
- Testing
- Exercise Training, Chemo only
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Early Breast Cancer, Radiation Associated Cardiac Failure
The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer
The majority of early breast cancer patients are treated with adjuvant radiation therapy (RT) as part of their multimodal therapy.
- Trial name
- NCT04291378
- Testing
- Proton versus photon radiation therapy
- Where
- 8 sites in Denmark
- Volunteers
- 1,502 people
- Sponsor
- Danish Breast Cancer Cooperative Group
HER2-positive Breast Cancer
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
To evaluate the pathology complete response rate (pathology Complete Response, pCR) of eribulin combined with trastuzumab + pertuzumab in neoadjuvant therapy for HER-2 positive early or locally advanced breast cancer.
- Trial name
- NCT05945368
- Testing
- Eribulin mesylate injection、Pertuzumab、Trastuzumab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients…
- Trial name
- EUTACAM (NCT04740697)
- Testing
- Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Claudius Regaud
Breast Cancer
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
The purpose of this research study is to compare the efficacy and safety of EG12014 with Herceptin as neoadjuvant treatment for 12 weeks, followed by surgery and subsequent EG12014 or Herceptin adjuvant treatment for up to 12…
- Trial name
- NCT03433313
- Testing
- EG12014, Herceptin
- Where
- 91 sites in United States, Belarus and 9 more
- Volunteers
- 807 people
- Sponsor
- EirGenix, Inc.